Mindray Displays New Generation Benchtop Cellular Analysis Line
|
By LabMedica International staff writers Posted on 31 Jan 2019 |

Image: The CAL 6000 benchtop cellular analysis line (Photo courtesy of Mindray).
Mindray (Shenzhen, China) exhibited its new generation benchtop cellular analysis line at MedLab Middle East, an international platform for laboratory management and medicine that brought together more than 700 exhibitors and over 35,000 professionals. MedLab Middle East 2019 took place at the Dubai International Convention and Exhibition Centre, Dubai, UAE from the 4th to the 7th of February.
Among Mindray’s latest innovations displayed at MedLab Middle East 2019 was CAL 6000, a benchtop cellular analysis line that connects two units of BC-6000 or BC-6200 auto hematology analyzers and one unit of SC-120 auto slide maker & stainer. The compact workstation helps save more laboratory space while delivering a fast throughput of up to 220 samples and 120 slides per hour. It provides automated body fluids test results, and is equipped with labXpert data management software for automatic sample validation and analysis.
At MedLab Middle East 2019, Mindray also exhibited the CL-900i chemiluminescence immunoassay analyzer, which has an industry-leading small benchtop footprint, a throughput of up to 180 tests per hour and 15 reagent positions. The CL-900i is a state-of-the-art system that is compact, fast and accurate, offering automation and reliable performance to ensure quality testing results with minimal hands-on time.
Among Mindray’s latest innovations displayed at MedLab Middle East 2019 was CAL 6000, a benchtop cellular analysis line that connects two units of BC-6000 or BC-6200 auto hematology analyzers and one unit of SC-120 auto slide maker & stainer. The compact workstation helps save more laboratory space while delivering a fast throughput of up to 220 samples and 120 slides per hour. It provides automated body fluids test results, and is equipped with labXpert data management software for automatic sample validation and analysis.
At MedLab Middle East 2019, Mindray also exhibited the CL-900i chemiluminescence immunoassay analyzer, which has an industry-leading small benchtop footprint, a throughput of up to 180 tests per hour and 15 reagent positions. The CL-900i is a state-of-the-art system that is compact, fast and accurate, offering automation and reliable performance to ensure quality testing results with minimal hands-on time.
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channelMultiprotein Plasma Panel Identifies Remission in Vasculitis
Vasculitis causes immune-mediated inflammation of blood vessel walls and can lead to kidney and lung damage. Clinicians rely on immunosuppressive drugs, but treatment carries significant side effects and... Read more
Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
Kidney transplantation remains constrained by organ scarcity and uncertainty about the quality of deceased-donor kidneys. In the United States, more than 92,000 people are awaiting a kidney transplant,... Read moreMolecular Diagnostics
view channel
New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
Many liquid biopsy strategies for monitoring breast cancer recurrence focus on detecting genetic mutations in tumor DNA. Researchers are evaluating whether additional features of circulating cell-free... Read more
Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
Breast cancer screening continues to face challenges, including limited detection of small tumors and uneven participation, particularly among women with dense breasts. These limitations can leave diagnostic... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read moreMicrobiology
view channel
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read morePathology
view channel
AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer
Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more








